Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
ActiveSite Pharmaceuticals
Berkeley, California, United States
- Ownership
- Private
- Employees
- ~2
- Development stage
- Other
01
Overview
ActiveSite Pharmaceuticals has demonstrated compelling proof-of-concept for orally administered plasma kallikrein inhibitors in animal models of diabetic macular edema and hereditary angioedema. The lead PK inhibitor has shown efficacy and safety in rodents and has advanced to IND-enabling toxicology studies, with clinical entry pending[3][5].
- Therapeutic areas
- ImmunologyOphthalmologyCardiovascular
- Modalities
- Small molecule
- Industry
- Biotech
02
Partnerships
AntriaBio
Beyond the preview
Go deeper on ActiveSite Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ActiveSite Pharmaceuticals.